Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 68,808 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the completion of the transaction, the director directly owned 357,567 shares in the company, valued at approximately $84,367,933.65. The trade was a 16.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jazz Pharmaceuticals Trading Up 0.8%
NASDAQ:JAZZ opened at $245.43 on Wednesday. The stock has a market capitalization of $15.75 billion, a price-to-earnings ratio of 83.48, a PEG ratio of 0.44 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 52 week low of $132.10 and a 52 week high of $266.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $229.26 and a 200 day moving average of $218.48.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.15. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the company earned $8.13 earnings per share. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the company. Private Advisor Group LLC boosted its position in Jazz Pharmaceuticals by 193.2% in the third quarter. Private Advisor Group LLC now owns 3,046 shares of the specialty pharmaceutical company's stock valued at $705,000 after buying an additional 2,007 shares during the last quarter. Ieq Capital LLC raised its position in Jazz Pharmaceuticals by 1,149.2% during the 3rd quarter. Ieq Capital LLC now owns 20,625 shares of the specialty pharmaceutical company's stock worth $4,775,000 after buying an additional 18,974 shares during the last quarter. Focus Advisor Solutions LLC raised its position in Jazz Pharmaceuticals by 75.2% during the 3rd quarter. Focus Advisor Solutions LLC now owns 2,802 shares of the specialty pharmaceutical company's stock worth $649,000 after buying an additional 1,203 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $302,000. Finally, HighTower Advisors LLC lifted its stake in Jazz Pharmaceuticals by 6.9% during the 3rd quarter. HighTower Advisors LLC now owns 7,268 shares of the specialty pharmaceutical company's stock valued at $1,683,000 after acquiring an additional 471 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.
Wall Street Analysts Forecast Growth
JAZZ has been the subject of several research analyst reports. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday. Needham & Company LLC boosted their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a research report on Wednesday, August 26th. Wells Fargo & Company upped their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Finally, Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, September 30th. They set a "buy" rating and a $325.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $293.00.
View Our Latest Report on JAZZ
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
